$BLFS

BIOLIFE SOLUTIONS INC

No enriched coverage for $BLFS in the last 7 days.

No SEC Form 4 filings for $BLFS in the last 30 days.

See all $BLFS insider activity →

BioLife Solutions director disposes of 57,995 shares

BioLife Solutions director Rachel Ellingson sold 57,995 shares on October 6, 2026, as part of a merger with Repligen. Each share was converted to $11.25 in cash and 0.1442 Repligen shares, per the merger agreement. Ellingson held no shares post-transaction.

BLFS sentiment & insider activity

Recent BLFS coverage spans insider activity and financial news.

What's driving BLFS

  • The insider sale may signal reduced confidence from the CFO, but no price was disclosed.

    SEC EDGAR · Oct 9, 2026

  • Insider director exited all positions, suggesting possible negative sentiment.

    SEC EDGAR · Oct 9, 2026

  • BioLife Solutions director Rachel Ellingson sold 57,995 shares on October 6, 2026, as part of a merger with Repligen. Each share was converted to $11.25 in cash and 0.1442 Repligen shares, per the merger agreement. Ellingson held no shares post-transaction.

    stocktitan.net · Oct 9, 2026

  • The insider sale may signal slight negative sentiment but the modest size limits impact.

    SEC EDGAR · Oct 9, 2026

  • The insider sale may signal reduced confidence from a director, potentially pressuring the stock.

    SEC EDGAR · Oct 9, 2026

AlphAI scores every news story that mentions BLFS with an AI model for sentiment and relevance, and aggregates insider trades from BIOLIFE SOLUTIONS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BLFS

Score